Amway has committed to a second-round investment with Holzapfel Effective Microbes (HEM), a company that supports people with incurable diseases related to microbiome disfunction.
HEM uses Personalized Pharmaceutical Meta-Analytical Screening (PMAS) to determine how gut microbiota can be leveraged to impact human health and wellness. This investment is the continuation of a partnership that began in 2020 as a way to develop personalized probiotics with the goal of supporting wellness through health benefits that stem from gut health.
“Amway is committed to increasing our investment in nutritional science, technology and innovation to provide solutions [for] the growing health and wellness needs of our Amway Business Owners (ABOs) and customers,” said Asha Gupta, Amway Regional President, Asia & Chief Strategy and Corporate Development Officer. “Partnering with HEM enables our ABOs to be at the forefront of providing innovative and personalized probiotic supplementation specific to a customers’ needs.”
Amway stated that it is actively pursuing collaboration with additional startups in this space, and will initially focus on scouting partners within South Korea, the U.S., China, Thailand and Indonesia.